| Distress Management Clinical Practice Guidelines in Oncology | 2003/07/01 | | 339 |
| Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology | 2018/04/01 | English | 337 |
| NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 | 2016/12/31 | English | 336 |
| Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | 2019/10/01 | | 334 |
| Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology | 2022/06/01 | | 334 |
| Hepatobiliary Cancers | 2009/04/01 | | 333 |
| The NCCN Guideline for Distress Management: A Case for Making Distress the Sixth Vital Sign | 2007/01/01 | | 328 |
| Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology | 2021/02/01 | | 327 |
| Gastric Cancer, Version 2.2013 | 2013/05/01 | English | 317 |
| NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018 | 2018/07/01 | English | 304 |
| Breast Cancer | 2009/02/01 | English | 293 |
| NCCN Guidelines Insights: Rectal Cancer, Version 6.2020 | 2020/07/01 | | 290 |
| Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology | 2017/07/01 | English | 288 |
| NCCN Guidelines Insights: Breast Cancer, Version 1.2017 | 2017/04/01 | English | 280 |
| Non–Small Cell Lung Cancer, Version 2.2013 | 2013/06/01 | English | 276 |
| Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | 2019/06/01 | | 275 |
| NCCN Guidelines Insights: Prostate Cancer, Version 1.2021 | 2021/02/01 | | 272 |
| Role of Immunotherapy in Triple-Negative Breast Cancer | 2020/04/01 | | 269 |
| Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | 2019/08/01 | | 265 |
| NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 | 2020/04/01 | | 257 |
| NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016 | 2016/03/01 | English | 256 |
| Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | 2019/04/01 | | 254 |
| Non–Small Cell Lung Cancer, Version 6.2015 | 2015/05/01 | English | 252 |
| Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal | 2020/04/01 | | 251 |
| Colon Cancer | 2009/09/01 | English | 248 |
| Bladder Cancer | 2013/04/01 | English | 246 |
| Prostate Cancer, Version 2.2014 | 2014/05/01 | English | 246 |
| NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018 | 2018/06/01 | English | 245 |
| Neuroendocrine Tumors, Version 1.2015 | 2015/01/01 | English | 245 |
| NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020 | 2020/03/01 | | 242 |